Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference

,

Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference

Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting – 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical validation study of Predictive Precision Medicine Platform FOSTER CITY, Calif., April 18, 2023 – Notable Labs, Inc. (“Notable”), a clinical stage […]

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

,

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

The merger agreement can be viewed from the link below: Merger Agreement  


10 Drug Discovery & Development Solution Providers of 2022 (Pharma Tech)

10 Drug Discovery & Development Solution Providers of 2022 (Pharma Tech)

Published 10/18/2022 Link to: https://www.pharmatechoutlook.com/notable-labs

Notable Labs Supports the MDS Foundation’s Move for MDS Walks

Notable Labs Supports the MDS Foundation’s Move for MDS Walks

Published 9/25/2022 In support of the MDS Foundation, Notable Labs took part in the “Move for MDS Walk”, a 5-cities event that brings together patients, family members and caregivers in the MDS community. Matt de Silva, Notable’s Founder and Executive Chairman, joined the event from Chicago, IL at Maggie Daley Park on September 25, 2022. […]

One company’s failed drug is this company’s ‘jewel’

One company’s failed drug is this company’s ‘jewel’

Dr. Thomas Bock, CEO of Notable, is helping the company develop a ‘new class’ of predictive precision medicines in oncology. Meagan Parrish, Lead Editor PharmaVoice Published May 2, 2022 – Many pharma execs find that a personal experience with a patient serves as a catalyst to enter the field. For Dr. Thomas Bock, CEO of […]

Notable Labs & VBL Merger Deck

, ,

Notable Labs & VBL Merger Deck

The merger deck can be downloaded from the link below: Notable Labs & VBL Merger Deck  

Notable Labs Corporate Update Call & Webinar

,

Notable Labs Corporate Update Call & Webinar

Webcast Join our public webcast by clicking on the link below: https://viavid.webcasts.com/starthere.jsp?ei=1600185&tp_key=4b7262a51e Phone (877) 407-9208 (U.S. and Canada) or (201) 493-6784 (international) Passcode: 13736622


Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference

,

Notable Labs Presents Clinical Platform Validation Data at the 2023 AACR Conference

Notable Labs Presents Clinical Platform Validation Data at the 2023 American Association for Cancer Research Annual Meeting – 100% accuracy predicting clinical responders with Notable’s PPMP with enhanced machine learning – – Fourth clinical validation study of Predictive Precision Medicine Platform FOSTER CITY, Calif., April 18, 2023 – Notable Labs, Inc. (“Notable”), a clinical stage […]

Notable Labs & VBL Merger Deck

, ,

Notable Labs & VBL Merger Deck

The merger deck can be downloaded from the link below: Notable Labs & VBL Merger Deck  

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

,

VBL Therapeutics and Notable Labs Announce Definitive Merger Agreement

The merger agreement can be viewed from the link below: Merger Agreement  

Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

Notable Expands Executive Leadership Team with Appointment of Dr. Kevin Lynch as Chief Business Officer

Industry Dealmaker Joins Notable to Accelerate In-licensing Strategy to Fuel Predictive Precision Platform and Pipeline Foster City, Calif., January 6, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, announced the appointment of Kevin Lynch, Ph.D., M.B.A, as Chief Business Officer. Dr. Lynch has decades of deal-making experience within pharma, and recently led […]

Notable Presents Clinical Validation Data from Two Phase 2 Trials in Adult and Pediatric Acute Myelogenous Leukemia at the 63rd American Society of Hematology (ASH) Annual Meeting

Notable Presents Clinical Validation Data from Two Phase 2 Trials in Adult and Pediatric Acute Myelogenous Leukemia at the 63rd American Society of Hematology (ASH) Annual Meeting

Studies demonstrate high correlation between predicted response by Notable’s predictive precision medicines platform and actual clinical response, short-term and at one year Interim analyses of studies with MD Anderson Cancer Center and Texas Children’s Hospital investigators corroborate platform prediction data from Standford University collaboration Foster City, Calif., December 16, 2021 – Notable Labs, Inc. (Notable), […]

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable and CicloMed Initiate Phase 1B/2A Clinical Trial of Fosciclopirox in Acute Myelogenous Leukemia Under Co-Development Agreement

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform With The Goal Of Assessing Patient Responsiveness To Fosciclopirox Foster City, Calif. and Kansas City, Mo., December 1, 2021 – Notable Labs, Inc. (Notable), a clinical-stage predictive precision therapeutics company and CicloMed LLC (CicloMed), a developmental-stage pharmaceutical company have initiated a Phase 1B/2A clinical trial of […]

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Notable Expands Executive Leadership Team with Appointment of Christopher Whitmore as Chief Financial Officer

Foster City, Calif., November 23, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, today announced the appointment of Chris Whitmore as Chief Financial Officer. In this role, Mr. Whitmore will be a key member of the executive leadership team and will lead Notable’s financial strategy, planning […]

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Clinical Data on the Notable Predictive Precision Medicines Platform Presented at the 63rd ASH Annual Meeting

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platformto Accelerate Clinical Development and Maximize Patient Outcomes Foster City, Calif., November 22, 2021 – Notable Labs, Inc. (Notable), a clinical-stage platform therapeutics company, today announced two abstracts have been accepted for poster presentation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition. “These two clinical […]

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Launches Therapeutic Pipeline by Acquiring Worldwide Development and Commercialization Rights to Volasertib

Notable Will Leverage Its High-Fidelity Predictive Precision Medicines Platform to Accelerate Clinical Trial Timelines and Maximize Patient Outcomes Volasertib is a PLK-1 inhibitor with therapeutic potential across a range of tumor types Foster City, Calif., November 11, 2021 – Notable Labs, Inc. (Notable), a pioneer and developer of predictive precision medicines, has obtained worldwide rights […]

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

Notable Labs to Attend BIO Digital 2021 Highlighting Predictive Technology Platform for Oncology

FOSTER CITY, CA – June 10, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced that it will be attending BIO Digital 2021, a key international biotech partnering event held virtually on June 14-18. During the conference Notable […]

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

Notable Labs to Present at ASCO 2021 Highlighting Prediction Technology Platform

FOSTER CITY, CA – June 4, 2021 — Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced top-line results from its clinical response prediction technology platform in a pediatric acute myeloid leukemia (AML) study to be presented at the 2021 […]

Notable Names Dr. Thomas A. Bock as CEO

Notable Names Dr. Thomas A. Bock as CEO

FOSTER CITY, CA – March 31, 2021 – Notable Labs Inc., a leader in technology-powered life science with a proprietary platform for predicting patient outcomes and accelerating precision drug development, today announced the appointment of Thomas A. Bock, MD, MBA, as Chief Executive Officer.

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

Notable Labs to Present Analysis of Hematologic Oncology Drug Sensitivity Data

FOSTER CITY, CA – January 26, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is hosting a live webinar on February 9th to unveil their integrative data platform.

Notable Labs to present at Biotech Showcase™ Digital 2021

Notable Labs to present at Biotech Showcase™ Digital 2021

FOSTER CITY, CA – January 8, 2021 – Notable Labs, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced that it is participating in Biotech Showcase™ 2021 and will be presenting the strategic plan for long-term growth.

Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

Join Notable Labs at the 62nd ASH Annual Meeting – Dec 5-8, 2020

FOSTER CITY, CA – Dec 3, 2020 – Dr. Michael Spinner, from Stanford University, Department of Medicine, Division of Oncology, will present at the 2020 Virtual ASH Annual Meeting an update to the recently published article in Blood Advances.

Notable Labs Announces Partnership With All4Cure

Notable Labs Announces Partnership With All4Cure

FOSTER CITY, CA and SEATTLE; Oct. 28, 2020 (Business Wire) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, and All4Cure, which has built a real world data powered network of patients, clinicians and researchers to dramatically improve outcomes for millions of patients with cancer, today announced their partnership.

Notable Labs Announces Addition of Thomas Bock to Board of Directors

Notable Labs Announces Addition of Thomas Bock to Board of Directors

FOSTER CITY, CA – Oct. 13, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, today announced the addition of Thomas A. Bock to its board of directors.

Notable Labs Enters Into Partnership With myTomorrows

Notable Labs Enters Into Partnership With myTomorrows

FOSTER CITY, CA – Sep. 24, 2020 – Notable, a functional precision medicine company, and myTomorrows, an integrated platform that links patients with an unmet medical need to treatments in development worldwide, are proud to announce their partnership.

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

Notable Launches New Clinical Study With Washington University School of Medicine Exploring Ex Vivo Drug Screening to Predict Chemotherapy Sensitivity and Resistance

FOSTER CITY, CA – Aug. 06, 2020 – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced a new precision oncology study with Washington University School of Medicine in St. Louis, exploring the feasibility of ex vivo drug screening to predict sensitivity and resistance to chemotherapy, and to identify novel synergies across a broad panel of anti-cancer therapies.

Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer

Notable Appoints Biotech Veteran Joseph Wagner PhD as Chief Scientific Officer

FOSTER CITY, CA – July 08, 2020 (GLOBE NEWSWIRE) – Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that Joseph Wagner, PhD, has joined the company as Chief Scientific Officer. Dr. Wagner.

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

Stanford study finds that Notable’s drug sensitivity screening platform can identify potentially useful drugs for MDS patients refractory to standard therapies

FOSTER CITY, CA – June 23, 2020 (GLOBE NEWSWIRE) — Notable, which is redefining cancer treatment by taking a functional approach to precision oncology in hematological cancers, announced today that the results of a Stanford study using its drug sensitivity screening platform have been published in Blood Advances (June 23, 2020; Volume 4, Issue 12).

Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

Notable and MDS Foundation Announce Partnership to Collaborate on Clinical MDS Trials and Advance Drug Therapies for MDS Patients

FOSTER CITY, CA – April 30, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, announced a partnership today with the MDS Foundation. MDS Foundation (MDSF) provides insight and information to families on upcoming clinical trials for myelodysplastic syndrome (MDS). As part of the partnership, Notable […]

Notable Announces Leadership Team Expansion

Notable Announces Leadership Team Expansion

FOSTER CITY, CA – April 09, 2020 (GLOBE NEWSWIRE) — Notable, a technology leader redefining cancer treatment through rapid drug development via a clinically validated platform, announced today its board has appointed veteran life science executive Laurie Heilmann as Chief Executive Officer. She succeeds founder Matt De Silva who will remain a member of Notable’s […]

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

MedTech Notable Labs launches rolling blood cancer trial to test its AI system

FOSTER CITY, CA – January 22, 2020 — Notable, which is redefining cancer treatment with its scientific technology platform to rapidly advance drug development, is launching its first self-sponsored clinical trial, designed from the ground up to help validate its cancer patient matching platform over the long term.

The 50 best workplaces for innovators

by fastcompany.com

Notable Named To Fast Company’s Inaugural List Of The 50 Best Workplaces for Innovators

by globenewswire.com

Cancer Drug Discovery Firm Notable Nabs $40M in Series B Funding Round

by genomeweb.com

Personalized cancer treatment startup Notable Labs nabs $40M Series B

by Kevin Truong

AI-focused Notable Labs score $40M in funding; Seattle Genetics/Astellas submit marketing application for enfortumab vedotin

by Natalie Grover

Notable raises $40 million to personalize cancer drug regimens

by Kyle Wiggers

Notable Labs lands $40M to expand AI-based cancer treatment tech

by Amirah Al Idrus

Notable Announces $40m Series B Round to Fuel Development of Its Drug Discovery Platform for Personalized Oncology

July 16, 2019

Blood cancer startup targets treatment personalization

By Hannah Norman

Stanford, Notable Labs and Tempus collaborate on personalized medicine research for blood cancer

By MedCity News

Notable Labs brings on 2 development executives ahead of its first blood cancer trials

By fiercebiotech.com

Oncology Startup Notable Labs Donates its First Pediatric Therapy to Repurposing Non­Profit

By globenewswire.com

Notable Labs Collaborator at ASH Shows Company’s Platform Predicts Ex Vivo Drug Response in Myeloid Neoplasms

By globenewswire.com

The Leukemia & Lymphoma Society Presents Man & Woman of the Year

By mwoy.org

Tech investors take a Warren Buffett approach to raising money for blood cancer research

By cnbc.com May 19, 2018

In the next few weeks, you can spend time with any one of these VCs and it will all go to charity

By techcrunch.com on May 17, 2018

Here’s the Problem with Today’s Human Clinical Trials

By fortune.com on March 20, 2018

Builders VC Backs Personalized Cancer Treatment

By wsj.com on September 06, 2017

Notable Labs Raises $10M in Series A

By 360dx.com on September 06, 2017

Notable Labs raises $10M for drug testing service to develop therapeutic index for oncologists

By medcitynews.com on September 06, 2017

Notable Labs nets $10M for personalized cancer treatment tech

By fiercebiotech.com on September 06, 2017

Notable Labs Raises $10 Million Series A Financing to Advance Personalized Cancer Treatments

By businesswire.com on September 06, 2017

Laboratory Monitoring

By tetrascience.com on June 15, 2017

A High Throughput Screening System to Identify Actionable Treatments for Cancer Patients

By biosero.com on June 15, 2017

These seven researchers are changing the face of biotech

By bizjournals.com on June 8, 2017

Interview: Notable Labs tackles cancer research with cutting-edge tech

By tetrascience.com on June 12, 2017

ELITE Tech-Know Geek Transon Nguyen of Notable Labs

By pm360online.com on May 22, 2017

ELITE Disrupter Matthew De Silva of Notable Labs

By pm360online.com on May 22, 2017

The 2017 PM360 Elite 100

By pm360online.com on May 21, 2017

Labcyte Announces Collaboration with Notable Labs to Apply Functional Cancer Cell Screening

By labcyte.com on Dec 7, 2016

Robots Race for the Cure

By robotics.org on Nov 17, 2016

Notable Labs Enters into a Collaboration Agreement with IntelliCyt to Develop a Phenotypic Personalized

By intellicyt.com on Jun 20, 2016

Biden Comes To Silicon Valley For Innovation In White House Cancer Moonshot Initiative

By TechCrunch on Feb 27, 2016

Matthew De Silva

By Forbes on Jan 4, 2016

How Scientists Can Thrive in the Startup World

By themacro.com on Nov 18, 2015

YC Alum Atomwise Raises $6 Million To Further The Advancement Of Artificial Intelligence In Drug Dis

By TechCrunch on Jun 3, 2015

A Look Inside Transcriptic’s New Biotech Testing Facility

By TechCrunch on Mar 25, 2015

Y Combinator demo-thon: Check out 5 favorites from Day 2 – Silicon Valley Business Journal

By Boston Tech Flash on Mar 25, 2015

The Top 10 Startups Of Y Combinator Winter ’15 Demo Day 2

By TechCrunch on Mar 25, 2015

47 Startups That Launched At Y Combinator Winter 2015 Demo Day 2

By TechCrunch on Mar 24, 2015

Y Combinator backs cancer drug combo testing service

By fiercebiotechit.com on Mar 13, 2015

YC-Backed Notable Labs Provides Personalized Medical Testing For Brain Cancer Patients

By TechCrunch on Mar 10, 2015